MX347504B - Formulaciones concentradas de proteina y usos de las mismas. - Google Patents

Formulaciones concentradas de proteina y usos de las mismas.

Info

Publication number
MX347504B
MX347504B MX2012010114A MX2012010114A MX347504B MX 347504 B MX347504 B MX 347504B MX 2012010114 A MX2012010114 A MX 2012010114A MX 2012010114 A MX2012010114 A MX 2012010114A MX 347504 B MX347504 B MX 347504B
Authority
MX
Mexico
Prior art keywords
formulations
concentrated protein
protein formulations
high concentration
protein drug
Prior art date
Application number
MX2012010114A
Other languages
English (en)
Other versions
MX2012010114A (es
Inventor
T Chen Tracy
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of MX2012010114A publication Critical patent/MX2012010114A/es
Publication of MX347504B publication Critical patent/MX347504B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación, caracterizad porque comprende una proteína concentrada en una cantidad mayor que 100 mg/ml y menor que 200 mg/ml, un tonificante de una sal y un regulador de pH presentes en una cantidad combinada de 100 mM a 120mM y un agente tensoactivo, en donde la formulación tiene una osmolaridad de menos que 290 mOsm y tiene una viscosidad de menos que 40.
MX2012010114A 2010-03-01 2011-03-01 Formulaciones concentradas de proteina y usos de las mismas. MX347504B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33919110P 2010-03-01 2010-03-01
PCT/US2011/026647 WO2011109365A2 (en) 2010-03-01 2011-03-01 Concentrated protein formulations and uses thereof

Publications (2)

Publication Number Publication Date
MX2012010114A MX2012010114A (es) 2013-01-29
MX347504B true MX347504B (es) 2017-04-28

Family

ID=44542798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010114A MX347504B (es) 2010-03-01 2011-03-01 Formulaciones concentradas de proteina y usos de las mismas.

Country Status (16)

Country Link
US (2) US9956165B2 (es)
EP (1) EP2542221A4 (es)
JP (2) JP5937523B2 (es)
KR (1) KR101853981B1 (es)
CN (2) CN102946861B (es)
AU (2) AU2011223805B2 (es)
BR (1) BR112012022223B1 (es)
CA (1) CA2794929C (es)
HK (1) HK1223835A1 (es)
IL (1) IL221748B (es)
MX (1) MX347504B (es)
NZ (1) NZ602685A (es)
RU (1) RU2626512C2 (es)
SG (1) SG184355A1 (es)
WO (1) WO2011109365A2 (es)
ZA (1) ZA201207331B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
NZ610592A (en) 2010-11-04 2015-03-27 Boehringer Ingelheim Int Anti-il-23 antibodies
US9364542B2 (en) * 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
HUE049282T2 (hu) 2012-09-07 2020-09-28 Coherus Biosciences Inc Adalimumab stabil vizes formulációi
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
IN2015KN00657A (es) * 2012-09-20 2015-07-17 Morphosys Ag
KR102435648B1 (ko) 2013-09-11 2022-08-25 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
WO2016029049A1 (en) * 2014-08-20 2016-02-25 Cytodyn Inc. Hiv antibody therapy as treatment substitute
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20170247460A1 (en) * 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
HUE047860T2 (hu) * 2015-02-09 2020-05-28 UCB Biopharma SRL Ellenanyagot tartalmazó gyógyászati készítmény
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
ES2862425T3 (es) * 2015-11-03 2021-10-07 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
AU2017305856A1 (en) 2016-08-05 2019-03-21 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
CA3235178A1 (en) * 2017-03-01 2018-09-07 Medimmmune Limited Formulations of monoclonal antibodies
WO2018210944A1 (en) * 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
BR112020002289A2 (pt) * 2017-08-03 2020-07-28 Jazz Pharmaceuticals Ireland Limited formulações compreendendo um ácido nucleico em uma alta concentração
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US20190085086A1 (en) 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122910A (en) 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
DK1441589T3 (da) * 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
AU2002351756A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP3578168A1 (en) * 2002-02-14 2019-12-11 Chugai Seiyaku Kabushiki Kaisha Formulation of antibody-containing solutions comprising a sugar as a stabilizer
CA2476901C (en) * 2002-02-22 2012-10-09 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
SI1946776T1 (sl) 2002-02-27 2017-07-31 Immunex Corporation Stabiliziran tnfr-fc sestavek, ki obsega arginin
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
JP5634009B2 (ja) 2004-05-12 2014-12-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア
EP1750751B1 (en) * 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
NO347263B1 (no) * 2005-11-01 2023-08-14 Wyeth Llc Fremgangsmåte for fremstilling av en Faktor IX formulering for intravenøs injeksjon
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma

Also Published As

Publication number Publication date
JP2013521296A (ja) 2013-06-10
EP2542221A2 (en) 2013-01-09
CN105521491B (zh) 2020-03-24
JP2016193911A (ja) 2016-11-17
JP6229007B2 (ja) 2017-11-08
IL221748B (en) 2019-09-26
CN102946861B (zh) 2016-01-20
BR112012022223A8 (pt) 2017-12-05
HK1223835A1 (zh) 2017-08-11
KR20130010898A (ko) 2013-01-29
US9956165B2 (en) 2018-05-01
CA2794929C (en) 2018-06-05
MX2012010114A (es) 2013-01-29
CN102946861A (zh) 2013-02-27
BR112012022223B1 (pt) 2022-08-09
NZ602685A (en) 2014-10-31
WO2011109365A2 (en) 2011-09-09
CN105521491A (zh) 2016-04-27
BR112012022223A2 (pt) 2016-07-05
SG184355A1 (en) 2012-11-29
AU2011223805A1 (en) 2012-10-25
AU2016200495B2 (en) 2017-11-09
ZA201207331B (en) 2014-07-30
CA2794929A1 (en) 2011-09-09
AU2016200495A1 (en) 2016-02-18
KR101853981B1 (ko) 2018-05-02
RU2012141655A (ru) 2014-04-10
WO2011109365A3 (en) 2012-01-05
JP5937523B2 (ja) 2016-06-22
EP2542221A4 (en) 2013-10-23
RU2626512C2 (ru) 2017-07-28
US20130216525A1 (en) 2013-08-22
US11571383B2 (en) 2023-02-07
US20180263898A1 (en) 2018-09-20
AU2011223805B2 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
PH12019500517A1 (en) Long-acting formulations of insulins
TN2014000431A1 (en) Antibody formulatoin
PH12014502778A1 (en) Antibody formulation
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
MY188825A (en) High-concentration monoclonal antibody formulations
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
WO2011104381A3 (en) Stable antibody containing compositions
AU2013334740A8 (en) Stable, low viscosity antibody formulation
EA201300875A1 (ru) Каротиноидные частицы и их применение
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
WO2014204988A3 (en) 5t4-targeted immunofusion molecule and methods
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
NZ702342A (en) Pharmaceutical formulation
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX2013005820A (es) Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.
WO2011133894A3 (en) Protein drug formulations and packages
EA201270717A3 (ru) Лиофилизированный препарат атф и комплекса витаминов группы в и атф и комплекс витаминов группы в виде инъекций
JP2013505038A5 (es)
Ilyin et al. Gender education of pre-school children

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CYTODYN INC.

FG Grant or registration